Compare Nvidia Corp (NVDA) vs TG Therapeutics Inc (TGTX) Price & Performance

Nvidia CorpTrade

TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Nvidia Corp vs TG Therapeutics Inc — how do they compare? Nvidia Corp trades at $206.91 (market cap $4.92T), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Nvidia Corp is far larger — about 595.6× TG Therapeutics Inc's market cap, and Nvidia Corp pays a 0.49% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

	NVDA	TGTX
Market Cap	$4.92T	$8.26B
Sector	Technology	Health
52-Week High	$235.75	$59.06
52-Week Low	$165.17	$26.39
Enterprise Value	$4.86T	$8.50B
Dividend Yield	0.49%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nvidia Corp

Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.

Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.

TG Therapeutics Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVDA

Amplify CWP Growth & Income ETF offers 10.69% yield with tech focus, rated a BUY for income portfolios.Seeking Alpha · 5 hours agoBullish Roundhill Magnificent Seven ETF offers equal exposure to top 7 mega-cap tech stocks but with higher risk and cost.24/7 Wall Street · 5 hours agoNeutral Nvidia faces pressure from cheaper Chinese chips but bets on AI and emerging tech for growthSeeking Alpha · 6 hours agoNeutral View details →

TGTX

Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholdersGlobeNewsWire · 5 days agoBearish View details →

About Nvidia Corp

NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.